Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 278

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 278
---
, 2023, following the termination of APx’s discussions with its final potential target PG, under APx’s former management and the Initial Sponsor, APx entered into a purchase agreement with the Initial Sponsor and the Sponsor (controlled by Mr.Bransfield), whereby the Initial Sponsor agreed to transfer to the Sponsor 3,342,188 Founder Shares and 6,936,250 Private Placement Warrants (collectively, the “Transferred Equity”) purchased at the time of APx’s IPO pursuant to a Private Placement Warrants Purchase Agreement, dated December 6, 2021. As consideration for the transfer, the Sponsor paid $1 for such Transferred Equity, and committed to pay up to $50,000 in expense related to APx’s regulatory filings. The Initial Sponsor retained 970,312 Founder Shares and 2,013,750 Private Placement Warrants, which equity was not a component of the Transferred Equity. Mr.Bransfield’s Sponsor acquired a controlling interest in the Founder Shares; however, the Initial Sponsor remained invested in APx as a minority investor. The transfer and all agreements executed in connection with the transfer (including the transactions contemplated therein) are referred to as the “Sponsor Alliance.” In connection with the Sponsor Alliance, APx, its officers and directors, the Initial Sponsor and the Sponsor entered into additional agreements whereby: (i) the Sponsor signed a joinder agreement to become a party to the letter agreement and the registration rights agreement, both dated December 6, 2021 and entered into in connection with the IPO, among APx, the Initial Sponsor and certain other shareholders of APx; and (ii) the letter agreement was amended by the parties thereto to add a section to not restrict the transfer of founder shares and private placement warrants in connection with the purchase agreement. On October 30, 2023, the Parent sent the first draft of the share purchase agreement for MultiplAI’s review. On November 1, Linklaters started the due diligence process for MultiplAI. On November 9, 2023, MultiplAI sent its comments with regard to the first draft of the share purchase agreement and, on November 14, 2023, representatives of MultiplAI and the Parent and their legal counsels had a conference call to discuss main issues pointed out by MultiplAI. On November 24, 2024, OmnigenicsAI sent a revised version of the share purchase agreement to MultiplAI. From November 24